From Biomarkers to Better Outcomes: The Impact of Immunotherapy on the Endometrial Cancer Landscape

Program Description

Endometrial cancer is the most common gynecologic malignancy in developed countries, yet outcomes remain poor for patients with advanced, recurrent, or high-risk disease. Black women in particular experience disproportionately higher mortality despite lower incidence and often less access to guideline-concordant care. Tailoring treatment based on individual patient characteristics, such as molecular biomarkers or genetic mutations, is becoming increasingly important in cancer care. This program will equip oncology pharmacists and managed care professionals to navigate rapidly evolving immunotherapy-based treatment paradigms by connecting molecular biomarkers with optimal regimen selection, sequencing, and utilization management in recurrent and metastatic settings. Through discussion of pivotal trials of immune checkpoint inhibitor–chemotherapy combinations and PARP inhibitor–based strategies and current guideline recommendations, pharmacists will gain practical skills to individualize therapy based on stage, histology, biomarker profile, prior treatment, toxicity risk, and patient-specific factors. The activity will also address real-world challenges with biomarker testing workflows, interpretation of results, adverse effect monitoring, and cost-effectiveness of molecular testing and immunotherapy, highlighting how evidence-based formulary design, prior authorization criteria, and other managed care tools can promote equitable access, improve quality of life, and support value-based, guideline-driven care across diverse patient populations.

Target audience: Managed Care Pharmacist, Oncology Pharmacist
Type of activity: Application
Release date: April 30, 2026
Expiration date: April 30, 2027
Learner level: Managed Care Pharmacist, Oncology Pharmacist
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the use of predictive biomarkers to guide treatment selection with immunotherapy-based regimens in endometrial cancer and determine implications for utilization management strategies.
• Explore the evolving role of immune checkpoint inhibitors in recurrent or advanced endometrial cancer, based on recent clinical evidence and guideline recommendations.
• Investigate the impact of equitable access to immunotherapy in endometrial cancer on clinical outcomes, patient quality of life, and total cost of care in managed care populations approach to optimizing outcomes and utilization management for the treatment of SLE and LN.

Accreditation

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-26-088-H01-P. The activity is available for CE credit through April 30, 2027.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Jennifer MacDonald, PharmD, BCOP, has the following relevant financial relationships with ineligible companies to disclose: Grant/Research Support: GSK, Verastem; Consultant: Verastem; Speakers Bureau: GSK

Simone Ndujiuba, PharmD, BCOP, has the following relevant financial relationship with an ineligible company to disclose: Former employee of PBM: Prime Therapeutics

Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Daphne Davis, PharmD, BCOP; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with ineligible companies to disclose.

Medical reviewer Erin Zacholski, PharmD, BCOP, has the following financial relationship with an ineligible company to disclose: Consultant (advisory board): Verastem

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms